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Background: Brain damage and cardiovascular disease are extra-pulmonary manifestations
of chronic obstructive pulmonary disease (COPD). Cardiovascular risk factors and smoking
are contributors to neurodegeneration. This study investigates whether there is a speciﬁc,
COPD-related deterioration in brain structure and function independent of cardiovascular
risk factors and smoking.
Materials and methods: Neuroimaging and clinical markers of brain structure (micro- and
macro-) and function (cognitive function and mood) were compared between 27 stable
COPD patients (age: 63.0±9.1 years, 59.3% male, forced expiratory volume in 1 second
[FEV1]: 58.1±18.0% pred.) and 23 non-COPD controls with >10 pack years smoking (age:
66.6±7.5 years, 52.2% male, FEV1: 100.6±19.1% pred.). Clinical relationships and group
interactions with brain structure were also tested. All statistical analyses included correction
for cardiovascular risk factors, smoking, and aortic stiffness.
Results: COPD patients had signiﬁcantly worse cognitive function (p=0.011), lower mood
(p=0.046), and greater gray matter atrophy (p=0.020). In COPD patients, lower mood was
associated with markers of white matter (WM) microstructural damage (p<0.001), and lower
lung function (FEV1/forced vital capacity and FEV1) with markers of both WM macro
(p=0.047) and microstructural damage (p=0.028).
Conclusion: COPD is associated with both structural (gray matter atrophy) and functional
(worse cognitive function and mood) brain changes that cannot be explained by measures of
cardiovascular risk, aortic stiffness, or smoking history alone. These results have important
implications to guide the development of new interventions to prevent or delay progression
of neuropsychiatric comorbidities in COPD. Relationships found between mood and micro-
structural abnormalities suggest that in COPD, anxiety, and depression may occur secondary
to WM damage. This could be used to better understand disabling symptoms such as
breathlessness, improve health status, and reduce hospital admissions.
Keywords: chronic lung disease, cigarette smoke, cognition, depression, MRI, neuroimaging
Introduction
Chronic obstructive pulmonary disease (COPD) is associated with a number of
extra-pulmonary, manifestations including cardiovascular disease, diabetes, arthri-
tis, osteoporosis, obesity, metabolic syndrome, muscle weakness, sleep disturbance,
and anemia.1,2 These occur at a higher rate than in smokers and never-smokers,3
have a deleterious effect on patient outcomes and wellbeing4,5 and contribute
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substantially to the ﬁnancial burden of the disease.6
However, the disease presentation is highly heterogeneous
and it is currently unclear whether these comorbidities are
pathogenically linked to the disease or reﬂect the co-exis-
tence of numerous age-related risk factors and conditions.7
Cognitive dysfunction, anxiety, and depression8–10 are
key comorbidities of COPD where they are associated
with greater disability,11,12 poorer medical compliance13 ,
increased risk of exacerbation,14 and mortality.11 However,
their pathophysiology in relation to COPD remains poorly
understood. Neuroimaging ﬁndings suggest that there are
underlying changes to brain structure and function asso-
ciated with both reduced lung function in the general
population and with established COPD.15–32 The pattern
of structural changes is consistent with cerebral small-
vessel disease (SVD).33 However, the majority of these
studies have failed to adequately control for individual
differences in cardiovascular risk and smoking history
(eg,17–23,25); factors known to accelerate age-related
SVD.34 Consequently, it cannot be established whether
this is a COPD-speciﬁc effect per se, or the cumulative
effect of greater cardiovascular risk in COPD.
The objectives of this study are to determine whether
COPD is associated with speciﬁc differences in brain
structure (macro- and micro-) and function (cognitive
function and mood) beyond those which can be attributed
to cardiovascular risk factors or smoking. This will be
achieved by cross-sectional comparison of a very well-
characterized cohort of COPD patients with age-matched
non-COPD control subjects with a history of smoking.
Additionally, the relationships between clinical measures
and brain structure and whether these relationships differ
between groups will be investigated in order to establish
whether the same disease processes are active in both
COPD patients and non-COPD smokers.
It is hypothesized that when compared to non-COPD
smokers, COPD patients will show evidence of differences
in brain structure and function that cannot be explained by
cardiovascular risk factors and smoking. It is predicted
that the pattern of differences in brain structure will be
consistent with age-related SVD.
Materials and methods
Study participants
Twenty-seven stable COPD patients (deﬁned as forced
expiratory volume in 1 second (FEV1)/forced vital capa-
city (FVC) <70% and/or clinical/radiological diagnosis of
emphysema who had not experienced an exacerbation
within the preceding 4 weeks) were recruited from inpa-
tient and outpatient clinics at North Bristol NHS Trust, and
23 non-COPD smoker controls were recruited from the
Bristol Primary Care Research North Hub between 2014
and 2015. All subjects provided written informed consent
for participation in the study. Inclusion criteria required all
subjects to be current or ex-smokers with greater than
10 pack years smoking history. Subjects were excluded
from participation if their resting oxygen saturations
(SaO2) were below 92% on room air, were on long-term
oxygen therapy, they had known alpha-1-anti-trypsin deﬁ-
ciency or co-morbid neurological, cardiovascular, or psy-
chiatric conditions likely to affect neuroimaging ﬁndings.
Subjects with incidental ﬁndings on neuroimaging, visual,
or hearing impairment that precluded neuropsychological
assessment or contraindications for magnetic resonance
imaging (MRI) were also excluded. For a full list of
inclusion and exclusion criteria see Table S1. Groups
were well matched for age, sex, educational attainment
category (deﬁned as, none, GCSE, A-level, degree or
other), body mass index, blood pressure, and smoking
status. However, COPD patients had smoked for a numeri-
cally greater number of pack years (see Table 1).
Ethics statement
Ethical approval was obtained from the NRES Committee
South West – Frenchay (13/SW/0319). The study was
conducted in accordance with the Declaration of Helsinki.
Procedure
The data used in this study formed part of a larger protocol,
therefore, data acquisition took place across three study
visits. Standard demographic information (age, sex, educa-
tional attainment category, smoking status, pack year his-
tory, body mass index) and clinical measures of disease
severity (post-bronchodilator spirometry performed as per
the recommendations of the American Thoracic Society and
European Respiratory Society Consensus Statement,35 dis-
ease status (COPD Assessment Test, CAT36), SaO2 (by
pulse oximetry), mood (Hospital Anxiety and Depression
Scale, HADS)37 and cognitive function (Montreal Cognitive
Assessment, MoCA)38 were collected on visit one. A brief
description of the HADS and MoCA can be found in the
Supplementary Material. Aortic stiffness (aortic pulse-wave
velocity and central augmentation index measured using
SphygmoCor system),39 blood pressure and earlobe capil-
lary blood gasses (PO2, PCO2, and pH)
40 were collected on
Spilling et al Dovepress
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visit two at the Respiratory Research Unit at the North
Bristol Lung Centre. MRI scans were acquired on visit
three at the Clinical Research Imaging Centre
(CRICBristol), Bristol University.
Image acquisition and processing
3-Tesla T1-weighted (T1W), ﬂuid-attenuated inversion
recovery (FLAIR) and diffusion tensor images (DTI)
were acquired for all subjects allowing measures of tissue
Table 1 Demographic and clinical characteristics
Controls COPD patients p
N 23 27 –
Age (years) 67±8 63±9 0.133a
Males (%) 52.2 59.3 0.776c
Educational attainment (%) None 30.4 40.7 0.473c
GCSE 52.2 37
A-Level 8.7 7.4
Degree 8.7 3.7
Other 0 11.1
Body mass index (kg/m2) 26.6±4.4 28.7±5.5 0.131a†
Cardiovascular risk
Smoking status (%) Ex-smoker 69.6 70.4 0.951c
Current 30.4 29.6
Smoking history (pack years) 31±15 40±21 0.051a†
Mean arterial pressure mmHg 97±10 98±10 0.826a†
Disease severity
COPD assessment test (CAT) 8±5 17±6 <0.001a†***
FEV1 (% pred.) 101±19 58±18 <0.001
a***
FVC (% pred.) 111±22 88±19 <0.001a***
FEV1/FVC (%) 78±11 54±14 <0.001
a***
Blood gases
PO2 (kPa) – 10.1 (1.4) –
PCO2 (kPa) – 5.2 (0.5) –
pH – 7.4 (0.3) –
SaO2 (%) 97 (2) 97 (3) 0.398
b‡
Aortic stiffness
Aortic pulse-wave velocity (m/s) 10.1 (3.4) 9.4 (3.6) 0.321b†
Central augmentation index (%) 29±7 28±8 0.932a†
Mood
HADS – anxiety 4±2 6±3 0.151a‡
HADS – depression 1 (4) 4 (4) 0.174b‡
HADS – total 7 (5) 9 (7) 0.046a‡*
Cognitive function
MoCA – total 28 (3) 26 (4) 0.011b‡**
Notes: Group comparison of demographic and clinical characteristics. For gaussian data raw unadjusted means ± standard deviations are presented, for frequency data raw
unadjusted group percentages are presented and for non-gaussian data raw unadjusted medians (interquartile ranges) are presented. aParametric ANCOVAs, bANCOVAs
performed on log10 transformed data,
cchi-squared tests. †Model includes age and sex as covariates of no interest, ‡model includes age, sex, smoking status, pack years
smoked, mean arterial pressure, and aortic pulse-wave velocity (+educational attainment for MoCA total) as confounders. Age and sex were not included in FEV1% pred. and
FVC % pred. analyses as they were already standardized for age and sex. *p<0.05, **p<0.01, ***p<0.001.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PO2, partial pressure of oxygen;
PCO2, partial pressure of carbon dioxide; CAT, COPD Assessment Test; HADS, Hospital Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment Test.
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macrostructure and tissue microstructure to be calculated.
Representative images for each group can be found in
Figure 1. This procedure is summarized below. For
detailed description of image acquisition and processing
see the Supplementary Material.
Tissue macrostructure
Supratentorial gray matter, white matter, and cerebrosp-
inal ﬂuid (CSF) tissue volumes were calculated from the
T1W images and white matter hyperintensities (WMHs)
volumes from the T1W and FLAIR images using a
semi-automated procedure described in Spilling et al
2017 and Lambert et al 2015.25,41 All volumes were
normalized for head size (% of total intracranial volume,
TIV).
Tissue microstructure
Fractional anisotropy (FA) (local tissue directionality)
and mean diffusivity (MD) (local magnitude of diffu-
sion) were calculated for each voxel of the DTI. The
median and normalized peak height of the distribution
of FA and MD values within the normal-appearing
white matter (NAWM) (white matter excluding
WMHs) were calculated.
Statistical analysis
Statistical analysis was performed using IBM SPSS
Statistics (IBM SPSS, version 24). Data residuals were
checked for Gaussian distribution using Shapiro–Wilk’s
tests, histograms, and quartile-quartile plots. Non-Gaussian
data were log10-transformed (or reﬂected and log10-trans-
formed). Group differences in clinical measures (including
demographic information, disease severity, aortic stiffness,
blood pressure, blood gases, mood, and cognitive function)
and brain macrostructure (normalized gray matter, white
matter, CSF, and WMH volumes) and microstructure (med-
ian FA, FA peak height, median MD, MD peak height) were
tested using analysis of covariance and chi-squared tests.
Relationships between clinical measures and brain structure,
and group interactions with these measures were tested
using multiple linear regression models. Post-hoc multiple
linear regression models were used to probe signiﬁcant
interactions. Results were considered signiﬁcant at p<0.05.
Unless indicated otherwise, all statistical analyses were
performed using models with demographic and cardiovas-
cular risk factors entered as covariates of no interest (age,
sex, smoking status, pack year history, mean arterial pres-
sure, and aortic pulse-wave velocity). Additionally, educa-
tional attainment category was included in any model
testing group differences or relationships with cognitive
function.
Results
Between-group differences
Clinical measures
Group comparisons of clinical measures can be found in
Table 1. As expected, COPD patients had signiﬁcantly
Figure 1 Representative macrostructural and microstructural images for COPD patients and non-COPD controls.
Notes: Macrostructural (T1W and FLAIR) and microstructural (FA and MD) images for a single representative subject from the COPD patient and non-COPD control
subject groups. Images are presented in native space using radiological convention, with FA and MD images shown without skull.
Abbreviations: COPD, chronic obstructive pulmonary disease; T1W, T1-weighted images; FLAIR, ﬂuid-attenuated inversion recovery; FA, fractional anisotropy; MD, mean
diffusivity.
Spilling et al Dovepress
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lower lung function (p<0.001) and worse disease status
(p<0.001) than non-COPD smoker controls, with unstandar-
dized regression coefﬁcients indicating that COPD was asso-
ciated with a decrease in FEV1 of 44% pred. and an increase
in CAT score of 10. Following correction for cardiovascular
risk, COPD patients had signiﬁcantly worse mood (p=0.046)
and following additional correction for educational attain-
ment, worse cognitive function (p=0.011) than non-COPD
smoker controls. Unstandardized regression coefﬁcients indi-
cated that COPD was associated with an increase in HADS –
total score of 3 points and decrease inMoCA – total score of 2
points. There were no group differences in SaO2 or in aortic
pulse-wave velocity and central augmentation index (see
Table 1).
Brain structure
Following correction for cardiovascular risk, COPD
patients were found to have signiﬁcantly lower normalized
gray matter volume than non-COPD smoker controls
(p=0.020). Unstandardized regression coefﬁcients indi-
cated that the presence of COPD was associated with
1.1% decrement in normalized gray matter volume. No
other signiﬁcant differences were found for measures of
brain macro- or microstructure (see Table 2).
Clinical relationships and group
interactions
Lung function, disease status, and blood gases
Multiple linear regression models assessing the main
effect and group interactions of lung function (FEV1
and FEV1/FVC) on brain structure showed that the
FEV1 model explained 37% of the variance in median
MD within the NAWM (r2=0.37, p=0.029) and that the
interaction between group and FEV1 signiﬁcantly pre-
dicted median MD (p=0.032). Post-hoc analysis indi-
cated that for COPD patients lower FEV1 was related
to greater median MD (p=0.028), but not for non-COPD
smoker controls (p=0.133). Similarly, multiple linear
regression models assessing the main effects and group
interactions of FEV1/FVC explained 43% of the var-
iance in normalized white matter volume (r2=0.43,
p=0.005) with the group interaction signiﬁcantly pre-
dicting normalized white matter volume (p=0.039).
Post-hoc analysis indicated that lower FEV1/FVC was
related to lower normalized white matter volume in
COPD patients (p=0.047) but not in non-COPD smoker
controls (p=0.461). These interactions are shown in
Figure 2A, B. No relationships were found between
CAT and SaO2 and brain structure.
Aortic stiffness
Multiple linear regression models found no signiﬁcant
main effects or group interactions of aortic stiffness (aortic
pulse-wave velocity and central augmentation index) on
brain structure.
Cognitive function
Multiple linear regression models assessing the main effect
and group interactions of MoCA – total score did not ﬁnd
any signiﬁcant relationships with brain structure.
Mood
The multiple linear regression model assessing the main
effects and group interactions of mood (HADS – total
score) on brain structure explained 38% of the variance
in median FA (r2=0.38, p=0.022), 34% of the variance in
median MD (r2=0.34, p=0.048) and 57% of the variance in
Table 2 Group differences in brain structure
Controls COPD patients F B p
Grey Matter Volume (% TIV) 42.6±1.4 42.0±1.7 5.823a‡ −1.090a‡ 0.020a‡*
White Matter Volume (% TIV) 27.9±2.6 28.1±1.7 0.031a‡ 0.117a‡ 0.861a‡
CSF Volume (% TIV) 29.5±2.5 29.8±2.6 1.714a‡ 0.973a‡ 0.198a‡
White Matter Hyperintensity Volume (% TIV) 0.22 (0.14) 0.30 (0.32) 0.163b‡ −0.046b‡ 0.689b‡
Median FA 0.43±0.01 0.42±0.02 0.748a‡ −0.005a‡ 0.392a‡
FA peak height (%) (×10–2) 2.88±0.16 2.82±0.11 0.579a‡ 0.000a‡ 0.451a‡
Median MD (×10–4 mm2/s) 7.44±0.17 7.52±0.37 0.799a‡ 0.000a‡ 0.377a‡
MD peak height (%) 0.18±0.02 0.18±0.02 1.000a‡ −0.006a‡ 0.323a‡
Notes: Group comparison of brain macro- and microstructure. For Gaussian raw unadjusted data means ± standard deviations are presented, for non-gaussian raw
unadjusted data medians (interquartile ranges) are presented. aParametric ANCOVAs, bANCOVAs performed on transformed data, F-statistics, unstandardized regression
coefﬁcients (B) and p-values are presented. ‡Model included age, sex, smoking status, pack years smoked, mean arterial pressure, and aortic pulse-wave velocity as covariates
of no interest. *p<0.05.
Abbreviations: TIV, total intracranial volume; CSF, cerebrospinal ﬂuid; FA, fractional anisotropy; MD, mean diffusivity.
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MD peak height (r2=0.57, p<0.001). It showed that there
were signiﬁcant main effects of greater HADS – total
score on lower median FA (p=0.009), lower MD peak
height (p=0.005) and higher median MD (p=0.038) and
group by total HADS score interactions for median FA
(p=0.011), median MD (p=0.012), and MD peak height
(p=0.020). Post-hoc analysis indicated that for COPD
patients higher HADS – total score was related to lower
median FA (p<0.001), lower MD peak height (p<0.001),
and higher median MD (p<0.001) whereas there were no
relationships for non-COPD smoker controls: median FA:
p=0.616; MD peak height: p=0.125 and median MD:
p=0.334. Graphs showing these interactions can be found
in Figure 2C, D.
Discussion
This study was designed to test whether COPD is an
additional independent risk factor for deterioration in
brain structure and function beyond that attributable to
age, traditional vascular risk factors, and smoking. COPD
patients showed evidence of greater cerebral atrophy,
lower cognitive function, and worse mood. Additionally,
exploratory tests of group interactions showed that lower
lung function (FEV1 and FEV1/FVC) was associated with
a deterioration in white matter macro- and microstructure,
and worse mood state was associated with a deterioration
in white matter microstructure in COPD patients but not in
non-COPD smokers.
Previous studies have shown that COPD and reduced
lung function are associated with a number of neuroima-
ging features of small-vessel cerebrovascular disease,
including small subcortical infarcts, WMHs, white matter
microstructural abnormalities, cerebral microbleeds, and
cerebral atrophy.15–29 Consequently, it has been suggested
that COPD-related deteriorations in brain structure and
function occur secondary to SVD15,42 either due to the
high prevalence of age-related vascular risk factors or
because COPD is itself a risk factor. Our study could not
replicate these white matter ﬁndings15,17,19,22,25 and we
suggest that they are likely to have been caused by group
differences in cardiovascular risk and smoking exposure.
However, in our study, COPD patients did have greater
cerebral atrophy, lower cognitive function and worse mood
state than non-COPD smokers and these could not be
explained by differences in cardiovascular risk factors or
smoking. The 1.1% decrement in normalized gray matter
volume associated with COPD in this study is greater than
the annual rate of gray matter volume and brain volume
decline reported in normal aging (ranging approximately
between 0.3% and 0.8%) eg,43–45 and SVD (0.9%).46 It is
Figure 2 Group interactions for the relationships between clinical measures and brain structure.
Notes: Post-hoc analyses of signiﬁcant group interactions using the predicted values from multiple linear regression models testing the relationships between: lung function
and white matter micro- and macrostructure (A, B), and mood and white matter microstructure (C, D). Age, sex, smoking status, pack years smoked, mean arterial
pressure, and aortic pulse-wave velocity were included as covariates of no interest. Red solid circles = COPD patients, Blue hollow circles = Non-COPD smoker controls.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; MD, mean diffusivity; FA,
fractional anisotropy.
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also similar in magnitude to the decrease in gray matter
volume cross-sectionally associated with diabetes mellitus
when compared to normal controls eg, 1.2%.47 Consistent
with Cleutjens et al,48 no relationships were found
between brain structure and the lower cognitive function
in COPD patients. However, signiﬁcant relationships were
found between reduced lung function and greater macro-
and microstructural white matter abnormalities in the
COPD patients which suggests that other mechanisms are
contributing to neurodegeneration and impaired cognition
and mood in COPD.
The generalized decrease in gray matter volume found
in this study has not been shown previously in COPD,
although other studies have reported localized reductions
in gray matter density, cortical thickness, and hippocampal
volume19–24 notably in regions associated with dyspnea
and fear of physical activity.19,20,24 We used a segmenta-
tion technique optimized for use in elderly cohorts with
WMHs,25,41 and use of this technique may have improved
sensitivity to detecting subtle gray matter alterations not
detectable in other studies. Alternatively, the inconsistency
in gray matter ﬁndings may reﬂect heterogeneity between
COPD cohorts.3
Like other chronic diseases, COPD is associated with a
higher prevalence of anxiety and depression than the gen-
eral population,49 with reported rates ranging from 7% to
50% and from 10% to 57%, respectively.10 Using the
HADS, the present study found some degree of anxiety
or depression in 39% and 22% of COPD patients, respec-
tively, with COPD patients having signiﬁcantly lower
overall mood than non-COPD smokers. Group interactions
were found such that worse mood was associated with
greater white matter microstructural abnormalities in
COPD patients but not in non-COPD smokers. Similar
cross-sectional relationships have been reported in normal
elderly and SVD cohorts where white matter alterations
(both in terms of white matter microstructural change and
severity of WMHs) were associated with higher incidence
of depressive disorder, greater disability, and lower depres-
sion remission rates.50–54 A recent meta-analysis found
that multiple markers of both cerebral (WMHs, micro-
bleeds, and microinfarctions) and peripheral forms
(plasma markers of endothelial dysfunction) of microvas-
cular dysfunction were associated with increased odds of
incident late-life depression.55 Furthermore, longitudinal
studies have suggested that markers of SVD may precede
the onset of depressive symptom.54,55 In these circum-
stances, it has been hypothesized that depression results
from localized disruption of frontostriatal white matter
networks involved in affective regulation.56 This is con-
sistent with functional MRI ﬁndings in COPD, which
show that COPD patients have an enhanced neural
responses in gray matter regions involved in emotional
processing and memory (including the medial prefrontal
cortex,31 anterior cingulate cortex,31 amygdala30, and
hippocampus30), to anticipation of dyspnea30 and dys-
pnea-related word-cues.31 These enhanced responses are
associated with worse perception of dyspnea,30 greater
anxiety30, and depression31 and worse disease status
(health-related quality of life and exercise tolerance).
Furthermore, it has been demonstrated to respond to pul-
monary rehabilitation.32 However, recent studies suggest
that frontostriatal network disruption leads to apathy rather
than depression in SVD.57,58
Advantages and limitations
This study beneﬁts from a well-deﬁned stable COPD
cohort and successful recruitment of a non-COPD cohort
with a history of smoking, allowing the effects of smoking
and COPD to be differentiated. The sample size is com-
parable to other similar MRI studies of the brain in
COPD,18–20,22,23,25 however, modest sample size may
limit the generalisability of these results in COPD patients
with other levels of disease severity. The secondary ana-
lyses testing for clinical relationships and group interac-
tion with brain measures were exploratory. The covariates
were grouped into pre-deﬁned clinically meaningful
domains to reduce multiple comparisons and linear regres-
sion models were adjusted for demographic and cardio-
vascular risk factors, however, we are unable to
completely exclude the possibility of type-I statistical
error due to multiple comparisons. This study used the
HADS to evaluate participants’ overall mood. This ques-
tionnaire was originally developed as a clinical screening
tool with two separate sub-scales measuring anxiety and
depression37 meaning that the present study has extended
its use beyond its original intent. The HADS has known
limitations in terms of the stability of this underlying
factor structure (particularly in disease)59 and ceiling
effects on individual items.60 A number of other authors
have supported the validity of using the total HADS score
(as in the present study) as a measure of overall psycho-
logical distress (eg,61–63). Serum cholesterol, a vascular
risk factor, was unavailable for this dataset and could not
be controlled for in statistical analyses.
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Conclusion
COPD is associated with a speciﬁc pattern of structural and
functional brain abnormalities that could not be explained by
conventional measures of cardiovascular risk, smoking history
or aortic stiffness. Worse lung function is associated with
deterioration in white matter macro- and microstructure, and
deterioration in white matter microstructure is associated with
lower mood. This suggests that mechanisms other than cardi-
ovascular risk and smoking contribute to brain changes in
COPD. Cognitive dysfunction, anxiety, and depression are
key comorbidities of COPD and are associated with greater
disability risk of exacerbation and mortality. COPD-related
anxiety and depression may occur secondary to white matter
damage. These ﬁndings have important implications for the
prevention and management of neuropsychiatric comorbid-
ities in COPD.
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Supplementary materials
Inclusion/Exclusion criteria
Clinical measures
Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item self-report questionnaire com-
prising two 7-item subscales measuring anxiety and
depression. It was originally developed as a clinical
screening tool for use in a general medical outpatient
setting and so explicitly excludes items that might be
confounded by somatic aspects of illness or serious
mental disorders.1
Montreal Cognitive Assessment (MoCA)
The MoCA is a brief 30-item cognitive assessment tool
designed to be sensitive to mild cognitive impairment in
individuals presenting with subjective cognitive
complaints.2 The MoCA has previously been applied to
chronic obstructive pulmonary disease (COPD) cohorts
where it has been shown to be sufﬁciently sensitive to
detect mild cognitive impairment in COPD patients with
moderate-severe disease.3
Image acquisition
All images were acquired with a 3-Tesla Siemens
Magnetron Skyra MRI scanner equipped with a 32-chan-
nel head coil with a maximum gradient strength of 45 mT/
m. Sagittal T1-weighted 3D volume (T1W) images were
acquired using a magnetization prepared rapid gradient
echo sequence (TE=2.25 ms, TR=1800 ms, TI=800 ms,
ﬂip angle 9°, 169 contiguous sagittal slices with a 0.9 mm3
isotropic voxel dimension and ﬁeld-of-view of 225
mm×240 mm×180 mm). Axial ﬂuid-attenuated inversion
recovery (FLAIR) was acquired using an inversion recov-
ery sequence (TE-126 ms, TR=11,000 ms, TI=2690 ms,
ﬂip angle=150°, with 60 contiguous slices, voxel dimen-
sion of 0.7 mm×0.7 mm×3 mm and ﬁeld-of-view of
201.25 mm×230 mm×180 mm). Diffusion tensor images
(DTI) were acquired using an echo-planar imaging
sequence with opposite phase-encode polarities (TE=76
ms, TR=6000 ms, ﬂip angle =90°, 55 contiguous axial
slices with a voxel dimension of 2.0 mm×2.0 mm×2.5
mm and ﬁeld-of-view of 192 mm×192 mm×137.5 mm).
For each phase-encode polarity, 8 volumes were acquired
without diffusion sensitization and 60 with non-collinear
diffusion gradients applied.
Image processing
Tissue macrostructure
The T1W images were re-sampled to 1 mm3 isotropic. The
FLAIR was afﬁne-registered to the T1W images using
Advanced Normalisation Tools4 and a semi-automatic pro-
cedure used to segment the T1W images into supra-tentor-
ial gray matter, white matter and cerebrospinal ﬂuid tissue
probability maps. White matter hyperintensities (WMHs)
were segmented using the combined image intensities
from the T1W and FLAIR images, then binarised at a
manually determined threshold (i.e., dichotomized so that
1=WMH and 0=non-WMH). This process is described in
full in Spilling et al, 2017 and Lambert et al, 2015.5,6
Tissue volumes were quantiﬁed by integrating the values
within each tissue segmentation and normalizing for head
size – calculated as a percentage of total intracranial
volume (gray matter + white matter + cerebrospinal
ﬂuid). Additionally, these tissue segmentations were used
to deﬁne regions of normal-appearing white matter
(NAWM) on the DTI (see below).
Table S1 Inclusion and exclusion criteria
Inclusion criteria
Informed consent
Aged 40–85 years
>10 pack year history
FEV1/FVC<70% (COPD only)
Exacerbation free for 4 weeks (COPD only)
FEV1/FVC>70% (Non-COPD smoking controls only)
Exclusion criteria
Resting SaO2<92% on room air
Known alpha-1 anti-trypsin deﬁciency
Pregnancy or lactating
Ischaemic heart disease
Cerebrovascular disease
Uncontrolled hypertension
Diabetes mellitus
Hepatic failure
Obstructive sleep apnoea
Non-cured tumors
Psychiatric disease that would impact on consent or compliance
Neurological disease
Known history of dementia
Current or past alcohol/drug abuse
Visual or hearing impairment that precluded neuropsychological
assessment
Contraindications for MRI
Incidental ﬁndings on MRI
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; COPD, chronic obstructive pulmonary disease; MRI, magnetic resonance
imaging.
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Tissue microstructure
The DTI data were corrected for movement artifacts,
eddy-current distortions, and susceptibility-induced local
gradients using FSL’s (FMRIB Software Library, version
5.0.6) “eddy”.7 The diffusion tensor model was ﬁtted at
every voxel within the DTI using FSL’s (FMRIB Software
Library, version 5.0.6) “dtiﬁt”,8 the skull removed using
FSL’s (FMRIB Software Library, version 5.0.6) Brain
Extraction Toolbox9 and mean diffusivity (MD) and frac-
tional anisotropy (FA) maps calculated from the DTI,
indicating the local magnitude and directionality of diffu-
sion, respectively.
T1W images were aligned to the DTI data using the
boundary-based registration procedure implemented in
FSL’s (FMRIB Software Library, version 5.0.6)
“epi-reg” script.10 This transformation was applied to
the T1W tissue segmentations and binary WMH map
(using trilinear interpolation) to align them with the
DTI. The WMH map was re-binarised at 0.5 creating a
WMH mask. These segmentations were used to deﬁne
the probability of the DTI voxels belonging to each
tissue-type. Voxels were considered to belong to the
supra-tentorial NAWM where the probability of belong-
ing to the white matter was higher than for any other
tissue-type providing that they were not included within
the WMH mask.
Normalized histograms (i.e. probability density func-
tions) of FA and MD values within the NAWM were
constructed using 100 equal bins ranging in value from 0
to 1 for FA and 0 to 2×10−4 mm2/s for MD. The median
and peak height values were used to characterize the dis-
tribution of these histograms.
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